Search
for
Sort by
Research 181–210 of 328
- Interleukin-15 is a hair follicle immune privilege guardian
- Clinical Trial Eligibility in Real‐World Alopecia Areata Patients Treated With Baricitinib
- Psoriasis Course in Patients with Alopecia Areata Undergoing Baricitinib Therapy
- Etrasimod for alopecia areata: The scenario for a less extensive and moderate form
- COLLAB: A Global Survey of Clinical and Laboratory Assessment in Alopecia Areata by Hair Specialists
- Diagnosis and Management of Alopecia Areata: A Saudi Expert Consensus Statement (2023)
- Management of comorbid Crohn's disease and alopecia universalis with upadacitinib and oral minoxidil.
- A Real-World Study of Steroid-Free Monotherapy with Tofacitinib in Severe and Therapy-Recalcitrant Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Cases: A Retrospective Analysis
- Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata
- The role of oclacitinib in the management of ischaemic dermatopathy in four dogs
- Alopecia Areata and Dexamethasone Mini-Pulse Therapy, A Prospective Cohort: Real World Evidence and Factors Related to Successful Response
- Oral Tofacitinib and Systemic Corticosteroids, Alone or in Combination, in Patients With Moderate-to-Severe Alopecia Areata: A Retrospective Study
- Alopecia areata following COVID-19 vaccine: a systematic review
- Exploring the efficacy of baricitinib in treating alopecia areata after failed Janus kinase inhibitor therapy
- II Consensus of the Brazilian Society of Dermatology for the treatment of alopecia areata
- Selective Expansion of Tregs Using the IL-2 Cytokine Antibody Complex Does Not Reverse Established Alopecia Areata in C3H/HeJ Mice
- The evaluation of JAK inhibitors on effect and safety in alopecia areata: a systematic review and meta-analysis of 2018 patients
- Efficacy and safety of baricitinib in patients with refractory alopecia areata
- Effective treatment of refractory alopecia areata in pediatric patients with oral abrocitinib
- Is polycystic ovarian syndrome and insulin resistance associated with abnormal uterine bleeding in adolescents?
- Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study
- Ruxolitinib Rescues Multiorgan Clinical Autoimmunity in Patients with APS-1
- The Impact of Immune-Modifying Treatments for Skin Diseases on the Immune Response to COVID-19 Vaccines: a Narrative Review
- Effectiveness and safety of Baricitinib in alopecia areata: a prospective cohort study
- Clinical characteristics, subtype classification, and prognostic factors of ophiasis: A retrospective study of 150 patients with therapeutic implications
- Psoriasis Course in Patients with Alopecia Areata Undergoing Baricitinib Therapy
- Proteomic Predictors of Baricitinib Response in Severe Alopecia Areata: CCL11 Flags a Refractory Phenotype
- 470 Exploring the possible involvement of skin-resident memory T cells in refractory chronic alopecia areata
- A 52-Week Real-Life Study of Baricitinib in Moderate to Severe Alopecia Areata: Clinical, Trichoscopic Assessment and Patient Reported Outcomes
- When JAK inhibitors are off the table: durable remission of severe alopecia areata with dexamethasone oral mini-pulse and a focused review